Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Jun;18(6):825–834. doi: 10.1177/1352458512438454

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2012

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 1. — Estimated efficacy versus risks of approved and experimental therapies for MS. The plot indicates estimated, approximate risks vs. efficacy measures for some approved and experimental MS treatments. Estimated risks of life threatening unwanted effects are obtained from data available in the current literature.^39–50 The percent relapse suppression observed in treated patients is presented as a surrogate of efficacy. The list of treatments is not meant to be exhaustive but to only include the agents that have immediate relevance for the HSCT trial design. Abbreviations: GA, glatiramer acetate; IFN-β, interferon beta; FTY, fingolimod; Mitox., mitoxantrone; CY, cyclophosphamide, Nataliz., natalizumab; Alemt., alemtuzumab, Hi-CY, high-dose cyclophosphamide, HSCT, autologous hematopoietic stem cell transplantation.